Loading...

PE Streptavidin

Pricing & Availability
Regulatory Status
RUO
Other Names
Streptavidin-Phycoerythrin, SAv-PE
Ave. Rating
Submit a Review
Product Citations
publications
SAV_PE_082808.jpg
C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
  • SAV_PE_082808.jpg
    C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
See PE spectral data
Cat # Size Price Quantity Check Availability Save
405203 100 µg 45€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
405204 500 µg 156€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Streptavidin binds to biotin with high affinity. Streptavidin-Phycoerythrin (PE) is useful for detecting biotinylated antibodies. The excitation of PE by 488 nm laser light induces a light emission maximum of 575 nm.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
Streptavidin is conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling
The streptavidin-PE solution should be stored undiluted between 2°C and 8°C, and protected from exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified
Recommended Usage

This streptavidin product is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the PE conjugation. For flow cytometric staining, the suggested use of this reagent is ≤0.06 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Streptavidin-Phycoerythrin (PE) is useful as a second step reagent for indirect immunofluorescent staining, when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-PE is 360 kD and Streptavidin alone is 52 kD.

Application References
  1. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245.
  2. Nishimoto KP,et al. 2008. J. Immunol. 181:4010.PubMed
  3. Niki T, et al. 2009. J. Biol. Chem. 284:32344. PubMed
  4. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed
  5. Scatizzi JC, et al. 2012. J. Immunol. 188:3307. PubMed
  6. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  7. Shibata T, et al. 2012. Int Immunol. 24:613. PubMed
  8. Baccala R, et al. 2012. J. Immunol. 189:5976. PubMed
  9. Grevers LC, et al. 2013. Ann Reheum Dis. 72:278. PubMed
  10. Woo SJ, et al. 2013. J Leukoc Biol. 93:363. PubMed
  11. Ashbaugh JJ, et al. 2013. J. Immunol. 190:4525. PubMed
  12. Reading JL, 2013. J. immunol. 190:4542. Pubmed.
  13. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  14. Gunaydin G, et al. 2014. Vaccine. 32:470. PubMed
  15. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  16. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  17. He X, et al. 2014. J Immunol. 193:1314. PubMed
  18. Wang W, et al. 2014. PNAS. 111:14466. PubMed
  19. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  20. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  21. Kim Yu, et al. 2015. PLoS One. 10:120294. PubMed
  22. Hua X, et al. 2015. PloS One. 10:128039. PubMed
Product Citations
  1. Zhang Y, et al. 2017. Journal of Immunological Methods. 10.1016/j.taap.2017.05.020. PubMed
  2. Wang H, et al. 2020. Mol Oncol. 14:991. PubMed
  3. Tas JMJ, et al. 2022. Immunity. 55:1856. PubMed
  4. Melzi E, et al. 2022. Immunity. 55:2168. PubMed
  5. Vyasamneni R, et al. 2023. Cell Rep Methods. 3:100388. PubMed
  6. Ke F, et al. 2023. Elife. 12:. PubMed
  7. Li D, et al. 2023. Int J Oncol. 62:. PubMed
  8. Silva RP, et al. 2023. Elife. 12:. PubMed
  9. Nozuma S, et al. 2023. JCI Insight. 8:. PubMed
  10. García-Vega M, et al. 2023. iScience. 26:106562. PubMed
  11. Liu Y, et al. 2023. Nat Commun. 14:2179. PubMed
  12. Fathi M, et al. 2023. iScience. 26:106482. PubMed
  13. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  14. Lv X, et al. 2023. Acta Pharm Sin B. 13:1631. PubMed
  15. Li X, et al. 2023. Nat Commun. 14:2929. PubMed
  16. Tundidor I, et al. 2023. Nat Commun. 14:3130. PubMed
  17. Chen K, et al. 2023. Gut Pathog. 15:28. PubMed
  18. Golubovskaya V, et al. 2023. Cancers (Basel). 15:. PubMed
  19. Martínez-Blanco Á, et al. 2021. Front Immunol. 12:713697. PubMed
  20. Wu Y, et al. 2021. Immunity. 54:2595. PubMed
  21. Goel RR, et al. 2022. Cell. 185:1875. PubMed
  22. Campisi L, et al. 2022. Nature. 606:945. PubMed
  23. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  24. Wu Y, et al. 2022. Sci Adv. 8:eabm7833. PubMed
  25. Cao Y, et al. 2023. Nature. 614:521. PubMed
  26. Weskamm LM, et al. 2022. STAR Protoc. 3:101902. PubMed
  27. Mekkaoui L, et al. 2023. Mol Ther Methods Clin Dev. 28:116. PubMed
  28. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  29. Hernandez SPA, et al. 2023. Front Immunol. 13:1035344. PubMed
  30. Pušnik J, et al. 2023. Nat Commun. 14:572. PubMed
  31. Knyphausen P, et al. 2023. Nat Commun. 14:768. PubMed
  32. Yeh CH, et al. 2022. Immunity. 55:272. PubMed
  33. Feng J, et al. 2022. Immunity. 55:405. PubMed
  34. Eger C, et al. 2016. PLoS One. 11: 0150479. PubMed
  35. Yang J, et al. 2016. Sci Rep. 6:38238. PubMed
  36. Chen T, et al. 2016. J Exp Med. 13(13):3025-3039. PubMed
  37. Lv X, et al. 2022. Acta Pharm Sin B. 12:735. PubMed
  38. Muliaditan T, et al. 2021. Cell Rep Med. 2:100457. PubMed
  39. Tian L, et al. 2021. Int J Mol Sci. 22: . PubMed
  40. Delás MJ, et al. 2019. Cell Rep. 27:719. PubMed
  41. Viborg N, et al. 2019. Oncoimmunology. 8:e1663107. PubMed
  42. Trendel N, et al. 2021. Sci Signal. 14:eaay9363. PubMed
  43. Gatineau J, et al. 2022. Front Immunol. 13:982839. PubMed
  44. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  45. Grevers L, et al. 2013. Ann Rheum Dis. 72:278. PubMed
  46. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  47. Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed
  48. Ruiz–Camp J, et al. 2019. EMBO Mol Med. 11:3. PubMed
  49. Nie X, et al. 2017. Cellular & Molecular Immunology. 10.1038/cmi.2017.17. PubMed
  50. Hernandez-Franco JF, et al. 2022. Front Immunol. 13:990900. PubMed
  51. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  52. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  53. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  54. Biswas S, et al. 2021. Nature. 591:464. PubMed
  55. Wellner A, et al. 2021. Nat Chem Biol. 17:1057. PubMed
  56. Gniffke EP, et al. 2020. medRxiv. . PubMed
  57. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  58. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  59. Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed
  60. Ashbaugh J, et al. 2013. J Immunol. 190:4525. PubMed
  61. Kim Y, et al. 2015. PLoS One. 10:120294. PubMed
  62. Yamamoto K, et al. 2021. Cell Reports. 36(8):109576. PubMed
  63. Nishimoto K, et al. 2008. J Immunol. 181:4010. PubMed
  64. Cao Y, et al. 2022. Nature. :. PubMed
  65. He X, et al. 2021. Emerg Microbes Infect. 10:1555. PubMed
  66. Im S, et al. 2016. Nature. 537:417-421. PubMed
  67. Schanda N, et al. 2021. Cells. 10:. PubMed
  68. Tsukamoto H, et al. 2013. Biochem Biophys Res Commun. 440:31. PubMed
  69. Phiwpan K, et al. 2015. PLoS One. 10:128198. PubMed
  70. Weiß S, et al. 2020. J Infect Dis. 222:1629. PubMed
  71. Niki T, et al. 2009. J Biol Chem. 284:32344. PubMed
  72. Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed
  73. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  74. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  75. Kristensen NP, et al. 2022. J Clin Invest. 132:. PubMed
  76. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  77. Cao Y, et al. 2022. Nature. 602:657. PubMed
  78. Rogers BM, et al. 2021. J Exp Med. 218:. PubMed
  79. Köchl R, et al. 2020. Elife. 9:00. PubMed
  80. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  81. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  82. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  83. Hansen UK, et al. 2020. Front Immunol. 11:373. PubMed
  84. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  85. Mei H, et al. 2021. J Hematol Oncol. 14:161. PubMed
  86. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  87. Reading J, et al. 2013. J Immunol. 190:4542. PubMed
  88. Weiß S, et al. 2020. medRxiv. . PubMed
  89. Hebbar N, et al. 2022. Nat Commun. 13:587. PubMed
  90. Tschismarov R, et al. 2021. JCI Insight. 6:. PubMed
  91. Richardson LS, et al. 2020. Lab Chip. 3.948611111. PubMed
  92. Van Gool F, et al. 2019. Immunity. 50:362. PubMed
  93. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  94. McWilliam H, et al. 2016. Nat Immunol. 17: 531-537. PubMed
  95. Zhang S, et al. 2016. Sci Transl Med. 8: 341ra77. PubMed
  96. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  97. Tsukamoto H, et al. 2017. FEBS Lett. 10.1002/1873-3468.12768. PubMed
  98. Parente-Pereira AC, et al. 2022. STAR Protoc. 3:101319. PubMed
  99. Baltierra-Uribe SL, et al. 2021. Eur J Immunol. 51:2641. PubMed
  100. Schoutrop E, et al. 2022. Oncoimmunology. 11:2093426. PubMed
  101. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  102. Mainini F, et al. 2015. PLoS One. 10: 0145403. PubMed
  103. Woo S, et al. 2013. J Leukoc Biol. 93:363. PubMed
  104. Baccala R, et al. 2012. J Immunol. 189:5976. PubMed
  105. Tian B, et al. 2017. Front Immunol. 10.3389/fimmu.2017.00956. PubMed
  106. Schoofs T et al. 2019. Immunity. 50(6):1513-1529 . PubMed
  107. Carestia A, et al. 2019. Cell Rep. 28:896. PubMed
  108. Scatizzi J, et al. 2012. J Immunol. 188:3307. PubMed
  109. Guo C, et al. 2021. Cell Rep Med. 2:100448. PubMed
  110. Chen YL, et al. 2021. J Biol Chem. :101420. PubMed
  111. Zhong MC, et al. 2021. J Exp Med. 218:. PubMed
  112. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  113. Günaydın G, et al. 2014. Vaccine. 32:470. PubMed
  114. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  115. Davis Z, et al. 2016. PLoS Pathog. 12: 1005421. PubMed
  116. Roewe J, et al. 2020. Nat Commun. 3.260416667. PubMed
  117. Leung EYL, et al. 2020. Mol Ther Oncolytics. 16:289. PubMed
  118. Nowak W, et al. 2020. EBioMedicine. 50:290-305.. PubMed
  119. Matsuda T, et al. 2022. iScience. 25:105324. PubMed
  120. Kim SP, et al. 2022. Cancer Immunol Res. :OF1. PubMed
  121. Cheloha RW, et al. 2021. RSC chem biol. 2:1692. PubMed
  122. Okamoto Y, et al. 2021. J Cell Sci. 134:. PubMed
  123. Gniffke EP, et al. 2020. J Infect Dis. 222:1965. PubMed
  124. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  125. Andersen TK, et al. 2019. NPJ Vaccines. 4:9. PubMed
  126. Lu X, et al. 2019. Cell Rep. 28:472. PubMed
  127. Hoffmann J, et al. 2021. Nat Commun. 12:3964. PubMed
  128. Wang W, et al. 2014. Proc Natl Acad Sci U S A. 111:14466. PubMed
  129. Miyauchi K, et al. 2016. Nat Immunol. 17:1447-1458. PubMed
  130. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  131. Dan JM, et al. 2021. Science. :371. PubMed
  132. He X, et al. 2014. J Immunol. 193:1314. PubMed
  133. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  134. Walker MR, et al. 2022. Sci Adv. 8:eabj9513. PubMed
  135. Yang Zhou J, et al. 2022. Front Immunol. 13:898473. PubMed
  136. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  137. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  138. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  139. Chappaz S, et al. 2010. J Immunol. 185:3514. PubMed
  140. Altman JB, et al. 2018. Health Sci Rep. 1:e74. PubMed
  141. Hirunwidchayarat W, et al. 2017. Biochem Biophys Res Commun. 10.1016/j.bbrc.2017.07.012. PubMed
  142. Wang EY, et al. 2022. Cell Rep Methods. 2:. PubMed
  143. Kurashima Y, et al. 2021. Nat Commun. 12:1067. PubMed
  144. Wells DK, et al. 2020. Cell. 183:818. PubMed
  145. Schürch CM, et al. 2020. Cell. 182:1341. PubMed
  146. DanDan Huang, Lang Bao 2016. J Microbiol Immunol Infect. 49:859-865. PubMed
  147. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  148. Pedersen NW, et al. 2019. Nat Commun. 10:837. PubMed
  149. Yang C, et al. 2019. Nat Commun. 10:3931. PubMed
  150. Xiao C, et al. 2021. STAR Protoc. 2:100789. PubMed
  151. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  152. Szeto C, et al. 2022. Nat Commun. 13:4951. PubMed
  153. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  154. Tripathi S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1555 - 1564. PubMed
  155. Ando Y, Oku T, Tsuji T 2016. PLoS One. 11: 0162208. PubMed
  156. Lautz JD, et al. 2019. Sci Rep. 9:10890. PubMed
  157. Kenney M, et al. 2017. Journal of Immunological Methods. 10.1016/j.jim.2017.07.001. PubMed
  158. Wirasinha RC, et al. 2021. J Exp Med. 218: . PubMed
  159. Holm JS, et al. 2022. Nat Commun. 13:1935. PubMed
  160. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  161. Yoshikawa S, et al. 2016. Sci Rep. 6:18738. PubMed
  162. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 6    Revision Date: 06/17/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account